Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy. (PubMed, J Cyst Fibros) - Sep 27, 2026 - "In this single center retrospective cohort analysis, we report sustained improvements in sinonasal disease and weight maintenance with preserved spirometric values over a mean follow up of 35.1 months on ETI compared to those not on therapy. We additionally present pharmacogenomic testing in a subset of our cohort as proof-of-concept for predicting DDIs at time of initiation of ETI."
Biomarker • Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Transplantation
|
|
Aderajew A Taddesse; Adil Sheikh; Ahmet Z Uluer; Amy E Hackmann; Ann E Woolley; Antonio Coppolino; Asma Algarawi; Benjamin A Raby; Benjamin J Kerman; Elizabeth Fieg; Ethan K Ito; George R Washko; Hilary J Goldberg; John C Kennedy; Kathryn Kear; Manuela Cernadas; Mohammed A Keshk; Rebecca E Cagnina; Ryan C Perkins; Sarah Kubiak; Selvin S Jacob; Stefi F Lee; Stella E Lee; Suzanne E Dahlberg; Yiyang Zhang
|